News

Click here to see our very own Dr. Barlin ESMO highlight on one of our current studies : ESMO 2024 Insights: Dose Optimization of Gotistobart + Pembro in Platinum-Resistant Ovarian Cancer - PRESERVE-004/GOG-3081 Study